Christopher Gresty

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer

Maha Hussain, Joaquı́n Mateo, Karim Fizazi et al. · New England Journal of Medicine · 2020 · 766 citations · Full text

Medicine, Oncology, Pharmacology +17

An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA -mutated ( gBRCA m) platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Yvette Drew, Maja J.A. de Jonge, Sook Hee Hong et al. · Gynecologic Oncology · 2018 · 130 citations

Medicine, Oncology, Pharmacology +16

Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Yvette Drew, Bella Kaufman, Susana Banerjee et al. · Annals of Oncology · 2019 · 95 citations · Full text

Medicine, Gynecology, Oncology +13

Abstract PD6-11: An open-label, multitumor, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline <i>BRCA</i> -mutated (g <i>BRCA</i> m) HER2-negative metastatic breast cancer (MBC)

S. M. Domchek, Sophie Postel‐Vinay, Y-J. Bang et al. · Cancer Research · 2018 · 50 citations

Medicine, Oncology, Pharmacology +17

Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)

Susan M. Domchek, S. Postel-Vinay, S.-A. Im et al. · Annals of Oncology · 2019 · 50 citations · Full text

Medicine, Oncology, Pharmacology +16